Groundbreaking results for type 1 diabetes and kidney health
Filed with ASX · · 3 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- June 2024 Quarterly Activities Report and Appendix 4C
- Eurobio Scientific to sell PromarkerD DKD test in France
- Proteomics appoints medical devices sales agency for Europe
- March 2024 Quarterly Activities Report and Appendix 4C
- Proteomics signs with Oxford Univ to validate test for Endo
Later from Proteomics International Laboratories
- Update on commercialisation of PromarkerD in the USA
- Esophageal cancer diagnostic delivers excellent results
- September 2024 Quarterly Activities Report and Appendix 4C
- AGM Chairman's Address and Investor Presentation
- Proteomics receives $2.16 million in R&D tax incentive
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories